Prevention of Hepatitis B Virus Vertical Transmission by Serovaccination and Tenofovir During Pregnancy

• Status: Completed
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The risk of vertical HBV transmission is related to HBV DNA level in pregnant women, around 30% in women with HBV DNA above 1, 000 000 I.U/mL despite serovaccination of newborns. Using tenofovir DF during the last trimester of pregnancy allows to reduce the risk, but data from Western countries are needed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hopital Lariboisière
• Treatments: Tenofovir

Criteria

Inclusion Criteria:

• pregnant women

• positive for HBs Ag

• HBV DNA above 100,000 I.U/mL

Exclusion Criteria:

• HIV co-infection

• HDV co-infection

• requiring, according to the physician's decision, a treatment for herself and not only to prevent HBV MTC transmission